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Vaccination of pigs againstClassical swine fever virus (CSFV) by using live-virus vaccines induces
early protection before detectable humoral immune responses. Immunological analyses indicate
that this is associated with T-cell activation, underlining the importance of targeting cytotoxic
T-lymphocyte (CTL) responses for vaccine improvement. Antigen-presenting cells (APCs)
transfected with mRNA encoding structural protein E2 or non-structural viral proteins NS3–NS4A
were used to identify viral genes encoding CTL epitopes. Monocyte-derived dendritic cells
(DCs) and fibrocytes served as the APCs. In vitro translation of the mRNA and microscopic
analysis of transfected cells demonstrated that E2 and NS3–NS4A could be identified. APCs
transfected with either of the mRNA molecules restimulated CSFV-specific T cells to produce
gamma interferon and specific cytotoxic activity against CSFV-infected target cells. The presence
of CTL epitopes on E2 was confirmed by using d/d-haplotype MAX cells expressing E2
constitutively as target cells in d/d-haplotype CTL assays. A potent CTL activity against E2 was
detected early (1–3 weeks) after CSFV challenge. This work corroborates the existence of CTL
epitopes within the non-structural protein domain NS3–NS4A of CSFV. Furthermore, epitopes on
the E2 protein can also now be classified as targets for CTLs, having important implications for
vaccine design, especially subunit vaccines. As for the use of mRNA-transfected APCs, this
represents a simple and efficient method to identify viral genes encoding CTL epitopes in outbred
populations.
INTRODUCTION
The development of new vaccines against members of
the family Flaviviridae is an issue of growing importance,
because these pathogens continue to present a medical and
economical problem in many areas of the world. The family
Flaviviridae comprises small, enveloped, single-stranded
RNA viruses, including the flaviviruses, the hepaciviruses
and the pestiviruses. Classical swine fever virus (CSFV) is a
highly contagious pestivirus that causes a severe and often
lethal disease of pigs, leading to important economic losses
worldwide. The CSFV genome is a positive-stranded RNA
molecule of about 12?3 kb, encoding a single open reading
frame (ORF) (Fig. 1a). This ORF is translated into a 3898 aa
polyprotein, which gives rise to the different CSFV proteins
after co- and post-translational processing (Meyers et al.,
1989). An autoprotease (Npro) located at the N terminus of
the polyprotein is followed by the structural proteins – core
(C), Erns, E1 and E2 – and the non-structural proteins – p7,
NS2, NS3, NS4A, NS4B, NS5A and NS5B (Meyers & Thiel,
1996).
Vaccination against CSFV with a C-strain vaccine induces
protection at least as early as 1 week post-vaccination. This
is interesting, because detectable neutralizing antibodies
usually appear at 2–4 weeks after vaccination (Terpstra et al.,
1990; Dahle & Liess, 1995; van Oirschot, 2003). An earlier
indication of immunological activity is the appearance
of CSFV-specific gamma interferon (IFN-c)-secreting cells
(SFCs) in the peripheral blood as early as 6 days after vac-
cination (Suradhat et al., 2001). Indeed, this was associated
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with protective immunity, indicating the importance of
cellular immunity during the early phases of immunity
against CSFV.
Consequently, the localization of T-cell epitopes – in
particular, epitopes recognized by cytotoxic T lymphocytes
(CTLs) – is important for new vaccine development and
improvement of existing vaccines, with respect to induc-
ing early protective immunity. Viral proteins capable of
inducing virus-specific T-cell responses have been examined
previously, and a nonapeptide CTL epitope was identified
on NS4A (Pauly et al., 1995). More recently, 26 different
pentadecapeptides capable of inducing virus-specific T-cell
responses have been found, distributed over different viral
proteins (Armengol et al., 2002). One of these peptides –
present on the NS2 protein – was shown to carry a CTL
epitope (Armengol et al., 2002). In contrast, no CTL epi-
topes have been identified on the CSFV structural proteins.
T-lymphocyte epitopes have to be recognized in the context
of major histocompatibility complex (MHC) molecules,
which imparts an influence of the MHC haplotypes on
epitope recognition. Considering that the above CTL epi-
topes were detected in d/d-haplotype inbred animals, it was
necessary to verify that CTL epitopes on CSFV proteins
would be recognized in outbred animals. To this end, we
employed a novel methodology based onmRNA-transfected
antigen-presenting cells (APCs) – both dendritic cells (DCs)
and fibrocytes were employed. DCs can be loaded effi-
ciently with mRNA molecules, leading to induction of
antigen-specific T-cell responses (Ponsaerts et al., 2003).
DCs transfected with mRNA encoding viral antigens can
induce strong, virus-specific CTL responses (Strobel et al.,
2000; Weissman et al., 2000; Zarei et al., 2003; Ueno et al.,
2004). Unlike the peptide-antigen approach, this methodo-
logy permits the identification of T-cell epitopes arising
naturally from the antigen processing by DCs and is there-
fore not influenced by the MHC haplotype. The procedure
is therefore particularly applicable to use with outbred
animals, and does not require the establishment of target-
cell lines for CTL assays. By using this approach of mRNA-
transfected DCs, the existence of T-cell epitopes recognized
by T lymphocytes from outbred animals was determined.
The mRNA-transfected DCs induced CSFV-specific res-
ponses efficiently, showing that CTL epitopes were present
on both non-structural proteins and the E2 structural
protein.
METHODS
Virus preparation. CSFV was prepared from SK-6 cells that were
infected at an m.o.i. of 0?01 TCID50 per cell and incubated for 72 h
at 39 uC, or from SK-6 cells expressing Erns for propagation of Flc23,
an Erns-deletion mutant (Widjojoatmodjo et al., 2000). Lysates from
these cultures and uninfected control cultures (mock) were prepared
as described previously (Knoetig et al., 1999).
Immunization of pigs against CSFV. Specific pathogen-free, 3-
month-old pigs (Swiss Land race), bred at the IVI, were infected
intranasally with 103 TCID50 vA187-1, a recombinant CSFV derived
from the Alfort/187 strain (Ruggli et al., 1996). Peripheral blood
Fig. 1. Overview of CSFV-derived mRNA molecules constructed. NTR, Non-translated region; Npro, p7, NS2, NS3, NS4A,
NS4B, NS5A and NS5B, non-structural proteins; C, Erns, E1 and E2, structural proteins; 59 CAP, 59-terminal capping; 39 b-
globin UTR, Xenopus laevis b-globin untranslated region; A70, 39-terminal poly(A) nucleotide stretch. (a) Linear map of the
recombinant CSFV ORF. The localization of the CSFV-specific CTL epitopes known for d/d-haplotype miniature pigs is
indicated (shaded boxes). (b) Constructed mRNA molecules with their respective lengths in bp. Amino acid positions are
indicated in italics. (c) Detection of eGFP and NS3 translated in vitro by Western blotting. After translation with the rabbit
reticulocyte lysate system and SDS-PAGE separation, the proteins were immunodetected by using an eGFP-specific mAb
and an NS3-specific polyclonal rabbit serum at the expected molecular masses (27 and 80 kDa, respectively).
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mononuclear cells (PBMCs) from these outbred animals were used
3–6 months after infection for the antigen-presentation assays using
transfected APCs.
For the CTL analyses using the MAX.b2 cells (see below), three
miniature pigs inbred for swine leukocyte-antigen complex (haplotype
d/d) were used (kindly obtained fromDrHenry Salmon, INRA, Tours-
Nouzilly, France). Three pigs were vaccinated intramuscularly with
104 immunofluorescence-stained ‘foci’ of vFlc23 complemented on
SK-6 cells expressing Erns (Widjojoatmodjo et al., 2000) at 2 months of
age. After 4 weeks, the pigs were challenged intranasally with 103?2
TCID50 CSFV strain Brescia 456610, corresponding to 100 LD50
(Terpstra & Wensvoort, 1988), followed by a second challenge after
8 weeks. This protocol was selected to induce a strong cellular immune
response with sufficient virus-specific T lymphocytes in the circula-
tion. Unvaccinated pigs were used as controls to determine the specifity
of the antigen-presentation assays.
Plasmids and mRNA molecules encoding CSFV-derived
genes. The E2 gene, including its signal sequence (sigE2), and the
sequences encoding NS3–NS4A of the CSFV genome (strain Alfort/
187; Fig. 1) were cloned into the pCR-XL-TOPO cloning vector
(Invitrogen). The sigE2 sequence, including the E2 gene and the
39-terminal 48 nt of the E1 gene, encoding the E2 signal sequence,
was amplified with primers sigE2_BamHI_L3 and E2_XbaI_R2; the
NS3–NS4A sequence was amplified with primers NS3_BglII_L
and NS4A_XbaI_R3. Subsequent cloning in the T7TSbetaglobinA70
vector (Hoerr et al., 2000; Carralot et al., 2004) (CureVac) was via
the BglII and the SpeI restriction sites, and the resulting vectors were
linearized by PstI followed by in vitro transcription using a T7-Opti-
mRNA transcription kit (CureVac). The 59-capped and polyadeny-
lated (A70), in vitro-transcribed mRNA molecules were purified by
LiCl precipitation, quantified, extracted with phenol/chloroform,
precipitated with ethanol/NaCl, washed with 75% (v/v) ethanol and
air-dried. All constructs were verified by sequencing on a LI-COR
4200 sequencer (LI-COR Biosciences). The sequences of the oligo-
nucleotide primers used were as follows [polarity of the primers: (+),
sense orientation; (2), antisense orientation]: sigE2_BamHI_L3(+),
59-CCGGATCCGCCACCATGATCGTGCAAGGTGTGATATG-39;
E2_XbaI_R2(2), 59-GGTCTAGATTAACCAGCGGCGAGTTGTTC-
TGT-39; NS3_BglII_L(+), 59-GAAACGCATAGATCTGCCGCCA-
CCGCCATGGGGCCTGCCGTTTGC-39; NS4A_XbaI_R3(2), 59-
GACGGCTCTAGATTATAGCTCTTTCAACTCTCT-39 (restriction
sites are shown in italics and start and stop codons are underlined).
Stabilized, capped and polyadenylated, in vitro-transcribed enhanced
green fluorescent protein (eGFP) mRNA molecules (produced from
the T7TSbetaglobinA70 vector) were purchased from CureVac.
For the construction of the pcDNA-E2/NS3 plasmid, viral RNA
isolated from CSFV strain Glentorf (GenBank accession no. U45478)-
infected cells was amplified by using primers with a BglII restriction site
at the 59 end (59-TTTTTTAGATCTATCGTGCAAGGTGTGATA-
TGGCTG-39) and a NotI restriction site at the 39 end (59-AAA-
AAAGCGGCCGCTCATAGACCAACTACTTGTTTTAGTGC-39) (res-
triction sites are shown in bold). To fuse the E2 and NS3 sequences,
overlapping primers were designed (forward primer E2–NS3, 59-
ACAGAACAACTCGCCGCTGGTGGTGGTATGCCAAGGGGCACC-
39; reverse primer E2–NS3, 59-GGTGCCCCTTGGCATAACACCA-
CCAGCGGCGAGTTGTTCTGT-39). After cDNA synthesis with avian
myeloblastosis virus reverse transcriptase (Boehringer Mannheim),
the E2–NS3 gene was amplified by PCR using the TripleMaster PCR
system (Eppendorf). The PCR product was purified, digested with BglII
and NotI and cloned into the pcDNA4 vector (Invitrogen), and the
inserted sequence was verified by sequencing.
In vitro translation of CSFV-specific mRNA and protein
detection by Western blotting. Proteins were expressed in vitro
by using the rabbit reticulocyte lysate system, using 1 mg RNA
translated in a 25 ml reaction without radioactive labelling, following
the manufacturer’s instructions (Promega). Proteins were separated
by SDS-PAGE under reducing conditions according to standard pro-
tocols and analysed by Western blotting. Gels were equilibrated for
30 min in SDS blotting buffer (12?5 mM Tris/HCl, 125 mM glycine,
0?05% SDS, 20% methanol, pH 8?3) prior to transfer to a Trans-
Blot nitrocellulose membrane (Bio-Rad) at 15 V for 30 min using a
Trans-Blot SemiDry transfer device (Bio-Rad). The membranes were
blocked for 1 h at room temperature with Odyssey blocking reagent
(LI-COR Biosciences) diluted 1 : 1 with PBS. Immunodetection was
performed for 30 min at room temperature with a mixture of the
eGFP-specific mAb JL8 (BD Biosciences) and a rabbit antiserum
against NS3 (J. D. Tratschin, unpublished data), followed by Alexa
Fluor 680 goat anti-mouse and anti-rabbit IgG (Molecular Probes)
secondary antibody, using standard protocols. Image acquisition
used the Odyssey Infrared Imaging system (LI-COR).
PBMC, DC and fibrocyte preparation. PBMCs were purified
from citrated blood by density-gradient centrifugation over Ficoll-
Paque (1?077 g l21; Amersham Biosciences) (McCullough et al.,
1993). For generation of DCs, monocytes were enriched from the
PBMCs by magnetic cell sorting using the magnetic-activated cell-
sorting (MACS) system (Miltenyi Biotec) and an anti-CD172a mAb
(74-22-15, kindly provided by Dr J. K. Lunney, USDA, Beltsville,
MD, USA) (Alvarez et al., 2000). DCs were cultured for 5 days at
39 uC, 6% (v/v) CO2 in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen) supplemented with 10% (v/v) porcine serum
(Sigma-Aldrich) and recombinant porcine (rp) granulocyte–
macrophage colony-stimulating factor (150 ng ml21, kindly pro-
vided by Dr S. Inumaru, Institute for Animal Health, Ibaraki, Japan)
and rp interleukin 4 (100 U ml21) (Carrasco et al., 2001).
Porcine fibrocytes were derived and cultured as described previously
(Balmelli et al., 2005). Briefly, PBMCs were plated at 46106 cells ml21
in fibrocyte medium [DMEM, 20% (v/v) fetal bovine serum (FBS), 1%
(v/v) penicillin/streptomycin (Invitrogen)]. After 24 h culture at 39 uC,
6% (v/v) CO2, non-adherent cells were removed by a single, gentle
aspiration. After 10–12 days further culture, the loosely adherent,
growing fibrocytes were further passaged or used as antigen-presenting
cells (Balmelli et al., 2005).
Transfection of SK-6 cells, DCs and fibrocytes. At 16 h before
transfection, SK-6 cells were detached by using trypsin/EDTA solu-
tion and plated in six-well plates with 105 cells per well. Prior to
transfection, the cells were rinsed twice with PBS. For the transfec-
tion, 2 mg mRNA (or 4 mg plasmid DNA) diluted in 1 ml Opti-
MEM was mixed with 8 ml TransFast lipofection reagent (Promega)
at a lipid :mRNA ratio of 4 : 1 (or 2 : 1 lipid : DNA ratio). After
15 min incubation at room temperature, the transfection mix was
added to the cells and incubated for 1 h at 37 uC. Following transfec-
tion, 4 ml pre-warmed Earl’s medium containing 7% (v/v) horse
serum was added to the cells. At 24 h post-transfection, the cells
were analysed for protein expression.
DCs were transfected by mRNA electroporation as described pre-
viously (Ceppi et al., 2005). Briefly, DCs were washed twice and
adjusted to 56106 cells ml21 in Opti-MEM (Invitrogen) in a 0?2 cm
gap electroporation cuvette (Bio-Rad). After 5 min on ice, 5 mg mRNA
was added and the cells were pulsed for 2–4 ms by using a Gene Pulser
II apparatus (300V, 125 mF; Bio-Rad) and cultured for another 48 h.
Fibrocytes were transfected by mRNA lipofection. At 4 h before
transfection, fibrocytes were plated in six-well plates with 0?56105–
1?06105 cells per well. Then, the cells were rinsed twice with PBS, and
3 mg mRNA diluted in 1 ml Opti-MEMwas mixed with 6 ml TransFast
(Promega) at a lipid :mRNA ratio of 2 : 1. After 15 min at room
temperature, the transfection mix was added to the cells and incubated
for 1 h at 39 uC. Following transfection, 4 ml fibrocyte medium was
added and, 24 h later, the cells were employed.
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Establishment of MAX cell lines expressing CSFV E2. MAX
cells, an SV40-immortalized swine kidney-cell line of MHC class I
haplotype d/d (Pauly et al., 1995), were grown in DMEM containing
5% (v/v) FBS, glutamine (0?3 mg ml21), penicillin (200 U ml21),
streptomycin (0?2 mg ml21) and mycostatin (100 U ml21). The
MAX cells were transfected with the pPRb2 plasmid containing
the E2 gene of CSFV strain Brescia (Widjojoatmodjo et al., 2000)
under control of the transcription and translation signals of the
pEVhisD12 vector (Peeters et al., 1992). For transfection, 2 mg
lipofectamine (Invitrogen) was diluted in 50 ml Opti-MEM I
(Invitrogen), mixed with plasmid DNA (1 mg) in 50 ml medium and
the mixture was incubated for 15 min at room temperature. MAX
cells grown in 10 cm2 tissue-culture plates were washed with Opti-
MEM I and cultured for 20 h in 0?5 ml medium. Then, the cells
were harvested for limiting-dilution cultures in microtitre plates in
medium containing 7?5 mM histidinol, which was replaced every
3–4 days until single colonies were visible. After 2 weeks, surviving
colonies were recloned by limiting dilution and screened for E2
expression by immunostaining with mAbs b3 and b6, directed
respectively against the conserved domain A and non-conserved
domain B of E2 from CSFV strain Brescia (Wensvoort et al., 1989).
The two domains were recognized by the mAbs in 70–80% of the
cells, referred to as MAX.b2.
Confocal-microscopy analysis. For CSFV-specific protein expres-
sion, transfected or infected cells were washed twice in PBS, fixed in
4% (w/v) paraformaldehyde for 15 min and washed again. Then,
the cells were stained for 20 min at 4 uC with the anti-E2 mAb
HC26 (Greiser-Wilke et al., 1990) (kindly provided by Bommeli
AG) or the anti-NS3 mAb C16 (Greiser-Wilke et al., 1992) (kindly
provided by Dr Greiser-Wilke, Hannover, Germany), diluted in
0?3% (w/v) saponin (S4521; Sigma-Aldrich) permeabilization solu-
tion. After washing with PBS containing 0?1% (w/v) saponin,
Alexa-488 or Alexa-546 fluorochrome-labelled anti-mouse secondary
antibody (Molecular Probes) – diluted in the permeabilizing solu-
tion – was added. Following incubation for 20 min at 4 uC, washing
and mounting in Mowiol mounting solution, the cells were analysed
by using a Leica TCS-SL spectral confocal microscope (CFM) and
Leica LCS software (Leica Microsystems AG).
Antigen-presentation assays. Purified T lymphocytes were
sorted by MACS using an anti-CD6 mAb, as described previously
(Carrasco et al., 2001). Purity of the positive fraction was >95%.
Either autologous DCs or fibrocytes (transfected or infected) were
employed as APCs at a ratio of 1 : 20 or 1 : 400, respectively. Where
indicated, CSFV strain Eystrup was added to the co-cultures at an
m.o.i. of 0?01 TCID50 per cell. These cultures were incubated for
5 days and then tested for the presence of activated T cells.
IFN-c ELISPOT. The ELISPOT assay was performed as described
previously (Armengol et al., 2002) with minor modifications.
Stimulated lymphocytes were added to duplicate wells on nitrocellu-
lose plates (Nunc) coated with mouse anti-pig IFN-c mAb (MP700,
5 mg ml21; Pierce Biotechnology). After 48 h incubation, IFN-c
spots were visualized with rabbit anti-pig IFN-c polyclonal antibody
(PP700, 2?5 mg ml21; Pierce Biotechnology) followed by peroxidase-
conjugated goat anti-rabbit antibody (Jackson Immunoresearch
Laboratories) and developed with 3,39-diaminobenzidine (Sigma)
for 20 min at room temperature in the dark. The number of spots
was determined with a computer-assisted video-image analyser (AID
ELISPOT reader; AID GmbH).
Cytotoxic assay. Autologous fibrocytes infected with CSFV were
used as target cells in a flow-cytometry assay for cytotoxicity
(Balmelli et al., 2005). Briefly, fibrocytes were detached, stained with
PKH26 (Sigma) and plated at 10 000 cells per well in 96-well flat-
bottomed plates. The fibrocytes were infected with CSFV or treated
with mock antigen for 24 h at an m.o.i. of 2 TCID50 per cell.
Restimulated lymphocytes (see above) were then added to the target
fibrocytes at various effector : target-cell (E : T) ratios for 16 h at
39 uC. Then, the percentage of dead cells was quantified by using
propidium iodide (Sigma).
For the experiments using d/d-haplotype MAX cells as target cells,
miniature pig-derived PBMCs were restimulated with CSFV strain
C1.1.1 (56106 p.f.u. ml21) for 7 days and CTL activity was tested in a
51Cr-release assay, as described previously (de Bruin et al., 2000).
Briefly, MAX.b2 cells, MAX cells transfected with an empty control
plasmid or infected MAX cells were labelled with 51Cr [400 mCi
(14?8 MBq); Amersham Biosciences, catalogue no. CJS4] and cultured
with restimulated PBMCs in 96-well V-bottomed microtitre plates
(Nunc) at E : T ratios decreasing from 50 to 6?25 for 5 h. The super-
natant was then tested for radioactivity in a Wallac Microbetaplus 1450
scintillation counter (EG&G Instruments). Maximal release of 51Cr
was induced by adding 50 ml 20% Triton X-100. Spontaneous release
was determined in wells that did not contain effector cells. The per-
centage of specific lysis was calculated as (c.p.m. experimental
release2c.p.m. spontaneous release)/(c.p.m. maximal release2c.p.m.
spontaneous release)6100.
Statistical analysis of data. Statistical evaluation of the experi-
mental data was performed by using Student’s t-test. A value of
P<0?05 was considered statistically significant.
RESULTS
mRNA molecules encoding CSFV-specific T-cell
epitopes
Two different mRNA molecules encoding CSFV-specific
T-cell epitopes were designed (Fig. 1b). The sigE2 mRNA
encodes the E2 structural protein and the C-terminal 16 aa
of the E1 protein with the E2 signal sequence. The NS3–
NS4A mRNA encodes the NS3 and NS4A non-structural
proteins, and should contain at least one CTL epitope on
the basis of peptide-antigen studies (Pauly et al., 1995). All
mRNA molecules have a common structure, characterized
by a 59-terminal cap, a 39 Xenopus laevis b-globin untrans-
lated region for mRNA stabilization and an A70 stretch at the
39 end (Fig. 1b).
As a first step, it was considered important to verify the
translation of the mRNA molecules. To this end, in vitro
translation in the rabbit reticulocyte lysate system followed
by Western blotting was used. Both eGFP and NS3 were
detectable with the expected molecular masses, indicat-
ing that both proteins are translated, although only NS3 at
lower levels (Fig. 1c). This technique was not used for the
E2 mRNA, due to the lack of a suitable antibody.
Expression of the E2 and NS3 proteins in
transfected cells
The protein-expression capacity of the CSFV-derived
mRNAs was tested in transfected cells and compared with
the expression obtained with plasmid DNA transfection or
CSFV infection. Protein expression was first tested in SK-6
cells, an established porcine cell line that is permissive for
CSFV infection and replication. At 24 h after lipofection of
pcDNA-E2/NS3 (for construct, see Fig. 1d), both E2 and
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NS3 were detectable (Fig. 2a, top panels). The proteins were
not detectable in all cells due to the limited transfection
efficiency of SK-6 cells (25%, relative to an eGFP reporter
plasmid). Moreover, in some cells, E2 and NS3 could not
be detected simultaneously, probably because of differences
in the sensitivity of their detection. Lipofection of SK-6 cells
with the sigE2 mRNA also resulted in E2 protein expression
(Fig. 2a, bottom panels). No signal for NS3 was detected
with the sigE2-transfected cells, as expected.
Having demonstrated the potential for transfection with
these constructs, translation of the mRNA molecules was
analysed in the immunological target for this work – DCs. At
24 h post-infection with CSFV, both E2 and NS3 were
detectable in DCs (Fig. 2b, top panels). When DCs were
electroporated with sigE2 mRNA, the E2 protein could
again be detected; this was noted in the majority of cells
as a focal inclusion. This appeared as a perinuclear inclu-
sion somewhat weaker than that obtained with transfected
SK-6 cells (Fig. 2b, bottom panels). The high number of
mRNA-transfected DCs expressing E2 was expected, as
electroporation of porcine DCs with eGFP mRNA results in
80% transfection efficiency (Ceppi et al., 2005). In contrast,
no NS3 could be detected by immunofluorescence in DCs
electroporated with NS3 mRNA (data not shown).
mRNA-transfected DCs induce CSFV-specific
CTL responses
Although only the E2 mRNA produced detectable protein
in the transfected DCs, it was necessary to determine
whether this had any immunological relevance. Conse-
quently, DCs transfected with the mRNA molecules
encoding E2 and NS3–NS4 were tested for their capacity
to induce virus-specific T-cell responses in vitro. The
mRNA-transfected DCs were co-cultured with CSFV-
immune lymphocytes at a ratio of 1 : 20, whilst CSFV-
infected DCs (m.o.i. of 0?01 TCID50 per cell) were employed
as a positive control. Mock-treated DCs were the negative
control. After 5 days DC/lymphocyte co-culture, the pres-
ence of activated T cells was determined by using an IFN-c
ELISPOT assay. As expected, the co-cultures using virus-
infected DCs yielded significantly higher numbers of IFN-c
SFCs than the mock-treated controls (Fig. 3a, ‘CSFV’ com-
pared with ‘Mock’; *P<0?05). The co-cultures using DCs
transfected with the different CSFV protein-encoding sigE2
Fig. 2. Detection of E2 and NS3 proteins in
transfected cells. (a) SK-6 cells were lipo-
fected with either a plasmid DNA encoding
the E2–NS3 fusion protein (pcDNA-E2/NS3,
top panels) or with the sigE2 mRNA (bottom
panels). (b) DCs were either infected with
CSFV (top panels) or electroporated with
sigE2 mRNA (bottom panels). At 24 h after
treatment, the cells were stained for intracyto-
plasmic E2 and NS3 proteins, using
specific mAbs, and imaged by confocal
microscopy.
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and NS3–NS4A mRNAs resulted in significantly higher
numbers of IFN-c SFCs compared with co-cultures employ-
ing eGFP-transfected DCs (Fig. 3a, ‘sigE2’ or ‘NS3–NS4A’
compared with ‘eGFP’; *P<0?05).
The presence of IFN-c SFCs indicates the induction of a
virus-specific T-lymphocyte response and can often relate to
the presence of CTL activity. In order to test this, lympho-
cytes from a CSFV-immune animal were stimulated with the
mRNA-transfected DCs and then incubated at various E : T
ratios by using virus-infected target cells of the same haplo-
type as the lymphocytes. A statistically significant three-
to fourfold increase in specific lysis of the target cells
was observed for the lymphocytes stimulated by sigE2-
transfected DCs, when compared with lymphocytes stimu-
lated by eGFP-transfected DCs (Fig. 3b, compare ‘sigE2’
and ‘eGFP’ in the graph and in Table 1; P<0?05). A
statistically significant two- to threefold increase in specific
lysis was observed for lymphocytes stimulated by NS3–
NS4A-transfected DCs (Fig. 3b, compare ‘NS3–NS4A’ and
‘eGFP’ in the graph and in Table 1; P<0?05). The results
demonstrate consistently that CSFV-specific CTL responses
were induced by sigE2 and NS3–NS4A mRNA-transfected
DCs. This demonstrated that CTL epitopes were encoded
within the structural E2 region.
Transfected fibrocytes are stimulators of CSFV-
specific CTL activity
Fibrocytes represent a population of blood-borne cells,
described recently as potent stimulators of CSFV-specific
CTLs (Balmelli et al., 2005). Consequently, fibrocytes trans-
fected with the above mRNA constructs were tested for their
capacity to activate CSFV-specific T cells. mRNA lipofec-
tion of fibrocytes using an eGFP mRNA reporter mol-
ecule resulted in 30% transfection efficiency and 92%
cell viability (data not shown). At 24 h after lipofection of
the fibrocytes, they were co-cultured with CSFV-immune
lymphocytes at a ratio of 1 : 400 (based on the known
characteristics of these cells; Balmelli et al., 2005). As a
positive control, CSFV-infected fibrocytes (m.o.i. of 0?01
TCID50 per cell) were employed and mock-treated fibro-
cytes were the negative control. After 5 days fibrocyte/
lymphocyte co-culture, the lymphocytes were tested for the
presence of activated T cells by the IFN-c ELISPOT assay.
The co-cultures of immune lymphocytes with virus-infected
fibrocytes yielded significantly higher numbers of IFN-c
SFCs compared with the mock-treated controls (Fig. 4,
‘CSFV’, ‘Mock’; *P<0?05). Similar to the DCs, co-cultures
of lymphocytes with fibrocytes transfected by using sigE2
or NS3–NS4A mRNA resulted in significantly higher num-
bers of IFN-c SFCs when compared with co-cultures of
lymphocytes with eGFP-transfected fibrocytes (Fig. 4;
*P<0?05).
MAX cells expressing E2 are killed efficiently
by CSFV-restimulated PBMCs
Due to the above results presented in Figs 3 and 4, it was
considered important to confirm the enhanced CTL activity
in an independent manner. To this end, MAX cells stably
expressing CSFV E2 protein were generated (MAX.b2 cells)
and used as target cells in CTL assays. MAX.b2 cells, but
not mock-transfected MAX cells (MAXtf ctrl), were lysed
by PBMCs restimulated with CSFV (Fig. 5a). Although the
cytotoxicity did not reach the same levels as CSFV-infected
MAX cells (MAX infected), the presence of E2 clearly
permitted a viral-specific CTL response. The cytotoxic
Fig. 3. Stimulation of antiviral CTL activity by mRNA-
transfected DCs. DCs were generated from CSFV-immunized
animals 3–6 months post-infection. At 48 h after mRNA trans-
fection, DCs were incubated with autologous lymphocytes at a
ratio of 1 : 20. As a positive control, DCs were infected with
CSFV (m.o.i. of 0?01 TCID50 per cell); the negative control was
mock-treated DCs. (a) After 5 days DC/lymphocyte co-
culture, the lymphocytes were analysed in an IFN-c ELISPOT
assay. Errors bars indicate the SD between replicate wells. The
result is representative of three independent experiments per-
formed with two different animals. *P<0?05 (paired t-test). (b)
The cytotoxic activity of the lymphocytes following 5 days co-
culture with transfected DCs was tested by using additional
cultures of CSFV-infected (m.o.i. of 2 TCID50 per cell) auto-
logous fibrocytes as target cells. The target cells were prepared
24 h prior to adding the stimulated lymphocytes (effector cells).
The result reported in the graph relates to experiment 1 in
Table 1 and is representative of three independent cytotoxic
assays performed with one animal.
Table 1. CTL responses induced by transfected DCs
Experiment sigE2 mRNA NS3–NS4A mRNA
1 3?6* 2?2
2 3?2 2?6
3 3?4 2?5
Mean±SD 3?4±0?2 2?4±0?2
*Fold increase compared with eGFP mRNA-transfected DCs at an
E : T ratio of 50.
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response that could be induced in PBMCs was then analysed
with cells isolated at different time points after vaccination.
High levels of CTL activity were detected at 1–3 weeks after
challenge (Fig. 5a, b), with a significant reduction 4 weeks
after challenge (Fig. 5c). The levels of cytotoxicity obtained
at this latter time point related to those seen when the
mRNA-transfected DCs or fibrocytes were employed to
stimulate lymphocytes obtained 3–6 months post-infection
(see Figs 3 and 4).
DISCUSSION
The present study presents a rationalized approach to iden-
tifying viral proteins containing CTL epitopes. T-cell epi-
topes are often identified by loading APCs with peptides
encoding epitopes or with proteins encoding whole anti-
gens. However, the production of peptides or sufficiently
pure proteins is both laborious and expensive. In contrast,
in vitro-transcribed mRNAs and the direct use of these
molecules to target APCs avoids such drawbacks, represent-
ing an alternative method for the identification of T-
cell epitopes (Strobel et al., 2000; Thornburg et al., 2000;
Weissman et al., 2000; Tuyaerts et al., 2003; Zarei et al., 2003;
Ueno et al., 2004). Importantly, APCs such as DCs can be
transfected efficiently with mRNA molecules, whereas gene
expression after plasmid DNA transfection is not detec-
table (Van Tendeloo et al., 2001; Ponsaerts et al., 2003;
Ceppi et al., 2005). Moreover, mRNA-transfected APCs
potentially display the complete spectrum of epitopes rele-
vant to a particular protein, rather than those present on the
synthesized peptides. This has the advantage of uncover-
ing previously unknown epitopes, but is particularly valu-
able in not suffering from restrictions imposed by MHC
haplotype – the APC will select the epitopes from the
translated proteins that fit best to their MHC haplotype.
Whilst DCs represent a well-established and potent APC, a
relatively new cell type has been identified with a propensity
for inducing CTL activity. This is the fibrocyte, an APC
derived from blood (Balmelli et al., 2005). Fibrocytes have
the additional advantage that they can be cultured easily
in the absence of cytokines and frozen as primary cell lines
Fig. 4. Stimulation of antiviral CTL activity by mRNA-
transfected fibrocytes. Fibrocytes were generated from CSFV-
immunized animals 3–6 months post-infection. At 24 h after
mRNA transfection, fibrocytes were incubated at a ratio of
1 : 400 with autologous lymphocytes. Positive controls were
fibrocytes infected with CSFV (m.o.i. of 0?01 TCID50 per cell),
whilst mock-treated fibrocytes served as negative controls. After
5 days fibrocyte/lymphocyte co-culture, the lymphocytes were
analysed in an IFN-c ELISPOT assay. Errors bars indicate the
SD between replicate wells. The result is representative of three
independent experiments performed with two different animals.
*P<0?05 (paired t-test).
Fig. 5. CTL activity against E2-expressing cells demonstrable in PBMCs of a challenge-infected pig. PBMCs were isolated
from pigs at 1 (a), 3 (b) or 4 (c) weeks after challenge with CSFV. These cells were restimulated in vitro with virus and tested
for their cytolytic activity in a 51Cr-release assay, using MAX cells infected with CSFV (MAX infected), MAX cells expressing
E2 (MAX.b2) or mock-transfected MAX cells (MAX-tf ctrl) as target cells. The specific cytotoxic activity at different E : T ratios
is shown for a experiment representative of three performed with three different animals.
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for future use. This makes them a particularly flexible alter-
native to monocyte-derived DCs for antigen-processing/
presentation studies.
Both DCs and fibrocytes were employed for the transfec-
tion studies. The mRNA used encoded the structural E2
protein or non-structural proteins NS3–NS4A of CSFV.
Transfection of APCs with the mRNA encoding E2 was
revealed easily, in terms of detecting the E2 protein by
immunofluorescent staining. In contrast, the NS3 pro-
tein could not be detected by immunofluorescence in
transfected cells, but was identified in immunoblots after
in vitro translation, albeit in low quantities. Furthermore,
APCs transfected with the mRNA encoding the non-
structural proteins were capable of restimulating T lympho-
cytes from immune animals, although any quantitative
comparison between the different mRNA-transfected APCs
is difficult. The difficulty in detecting the viral protein in situ
could be the result of viral or cellular protease digestion.
Furthermore, the formation of defective ribosomal pro-
ducts (DRiPs) – resulting from translational and post-
translational errors – could have been involved (Schubert
et al., 2000). There is evidence showing that DRiPs are
a major source of peptides presented in the context of
MHC class I (Yewdell et al., 2001) and could therefore
play a role in the antigen processing of mRNA-loaded
APCs.
This is the first report demonstrating CTL epitopes on
CSFV E2. Flavivirus-specific CTL epitopes have mainly been
identified on the viral non-structural proteins (Roehrig,
2003); nevertheless, reports demonstrating the presence of
CTL epitopes on the structural proteins of Hepatitis C virus,
including E2 (Koziel et al., 1993; Sarobe et al., 2001), are
related to our study, considering that both viruses are in the
family Flaviviridae.
These findings could be of importance for future vaccine
design, considering the immunology of CSFV. Although
the presence of neutralizing anti-E2 antibodies can be
related to protective immunity against CSFV, pigs can be
protected in the absence of such antibodies, such as
1–3 weeks after vaccination (Terpstra & Wensvoort, 1988;
Dewulf et al., 2004). Cellular immunity has been identified
as early as 1 week post-vaccination, in the form of IFN-c
SFCs (Suradhat et al., 2001). The present work demon-
strates that E2-specific CTL activity is particularly
evident 1–3 weeks after challenge. With CSFV being non-
cytopathogenic and the inaccessibility of the cell-associated
virus to neutralizing antibodies, CTL-based immune
defences have an important role to play.
Both the CTL epitopes and major epitopes for induc-
ing neutralizing antibodies should be targeted in novel
CSFV vaccines. The application of mRNA vaccines or self-
replicating pestivirus replicons are known to induce potent
CTL responses (Hoerr et al., 2000; Racanelli et al., 2004).
Such replicon-based vaccines have been described for
classical swine fever (Widjojoatmodjo et al., 2000; van
Gennip et al., 2002; Maurer et al., 2005) and represent pro-
mising vaccine candidates. However, such vaccines could
possibly lose immunogenicity if E2 is deleted or replaced
by a heterologous E2 from another pestivirus. On the other
hand, for subunit protein vaccines based on E2, the pre-
sent study would indicate that protein-delivery systems
suitable for the induction of both neutralizing antibodies
and CTL response have to be investigated. Therein, those
systems known to mediate cross-presentation, such as lipo-
somes, bacterial toxins, heat-shock proteins and particles,
are particularly interesting (Bungener et al., 2002; Chikh &
Schutze-Redelmeier, 2002; Moro´n et al., 2004).
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